Australian biotech market watch 19/03/10

At the end of a buoyant week for the stock market, the All Ordinaries is flat as of midday today, up a marginal 6.5 points to 4,884.20.

After Cochlear (ASX:COH) announced a change of chairman as Tommie Bergman indicated he was to step down, stocks in the company have seen a bump, up 3.86% since the announcement to $69.30 today.

Two of the other Big Three have remained fairly steady, with CSL (ASX:CSL) hovering around the $36 mark and ResMed loitering around $6.73.

Xenotransplantation specialists, Living Cell Technology (ASX:LCT), saw a steep rise early in the week, but much of the gains have been lost Thursday and today, with it dropping 2c to 21c, although that's still above the sub-20c mark it was trading at last week.

Mesoblast (ASX:MSB) is fairly steady today, up 1c to $2.06, but saw a tidy 5% lift in yesterday's trading.

Comments